• Johnson & Johnson disclosed long-term CARTITUDE-2 data showing CARVYKTI delivered sustained treatment-free remissions for many early-line relapsed myeloma patients.
• Results were presented at the International Myeloma Society annual meeting.
• Findings support a strategy to move the CAR-T earlier in care, aiming to deepen durability without ongoing maintenance therapy.
• Safety with longer follow-up stayed broadly consistent with prior experience, with no new CAR-T neurotoxicity signals flagged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: NY56384) on September 25, 2026, and is solely responsible for the information contained therein.